Ningyu Wang

Chengdu, 610031, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Design and synthesis of the first PARP1 and PRMT5 dual inhibitors for the treatment of breast cancer.

Design and synthesis of the first PARP1 and PRMT5 dual inhibitors for the treatment of breast cancer.

Journal: European journal of medicinal chemistry

Published: May 15, 2026

Design synthesis and biological evaluation of novel BCL6/GSPT1 degrader as anti-DLBCL agent.

Design synthesis and biological evaluation of novel BCL6/GSPT1 degrader as anti-DLBCL agent.

Journal: European journal of medicinal chemistry

Published: November 23, 2025

Design, synthesis, and biological evaluation of novel PROTACs based on unnatural dipeptide CRBN ligands.

Design, synthesis, and biological evaluation of novel PROTACs based on unnatural dipeptide CRBN ligands.

Journal: European journal of medicinal chemistry

Published: August 21, 2025

Polymerase theta (Polθ) and cancer: Role in tumor progression and potential as a therapeutic target.

Polymerase theta (Polθ) and cancer: Role in tumor progression and potential as a therapeutic target.

Journal: European journal of medicinal chemistry

Published: July 31, 2025

Design, synthesis and biological evaluation of 8-phenylquinazolin-2-amine derivatives as FLT3 covalent inhibitors targeting cysteine 828 in the ATP pocket.

Design, synthesis and biological evaluation of 8-phenylquinazolin-2-amine derivatives as FLT3 covalent inhibitors targeting cysteine 828 in the ATP pocket.

Journal: European journal of medicinal chemistry

Published: July 23, 2025

Discovery of a Potent FLT3 Inhibitor (E)-4-(3-(3-Fluoro-4-(morpholinomethyl)styryl)-1H-indazol-6-yl)pyridin-2-amine for the Treatment of Acute Myeloid Leukemia with Multiple FLT3 Mutations.

Discovery of a Potent FLT3 Inhibitor (E)-4-(3-(3-Fluoro-4-(morpholinomethyl)styryl)-1H-indazol-6-yl)pyridin-2-amine for the Treatment of Acute Myeloid Leukemia with Multiple FLT3 Mutations.

Journal: Journal of medicinal chemistry

Published: May 19, 2025

Design, synthesis, and biological evaluation of novel PI3Kδ/HDAC6 dual inhibitors for the treatment of non-Hodgkin's lymphoma.

Design, synthesis, and biological evaluation of novel PI3Kδ/HDAC6 dual inhibitors for the treatment of non-Hodgkin's lymphoma.

Journal: European journal of medicinal chemistry

Published: April 22, 2025

Polyphyllin I inhibits ovarian cancer growth by inducing G0/G1 phase arrest and inhibiting the c-Myc signaling pathway.

Polyphyllin I inhibits ovarian cancer growth by inducing G0/G1 phase arrest and inhibiting the c-Myc signaling pathway.

Journal: Medical oncology (Northwood, London, England)

Published: March 18, 2025

Design, synthesis and biological evaluation of 3-amino-6-(2-hydroxyphenyl)pyridazin-4-aryl derivatives as SMARCA2/4 degraders.

Design, synthesis and biological evaluation of 3-amino-6-(2-hydroxyphenyl)pyridazin-4-aryl derivatives as SMARCA2/4 degraders.

Journal: European journal of medicinal chemistry

Published: December 30, 2024

Fasting enhances the efficacy of Sorafenib in breast cancer via mitophagy mediated ROS-driven p53 pathway.

Fasting enhances the efficacy of Sorafenib in breast cancer via mitophagy mediated ROS-driven p53 pathway.

Journal: Free radical biology & medicine

Published: November 28, 2024

Correction to "Unleashing the Potential of Camptothecin: Exploring Innovative Strategies for Structural Modification and Therapeutic Advancements".

Correction to "Unleashing the Potential of Camptothecin: Exploring Innovative Strategies for Structural Modification and Therapeutic Advancements".

Journal: Journal of medicinal chemistry

Published: May 22, 2024

Design, synthesis and biological evaluation of new RNF126-based p300/CBP degraders.

Design, synthesis and biological evaluation of new RNF126-based p300/CBP degraders.

Journal: Bioorganic chemistry

Published: March 14, 2024

Showing 1-12 of 49

Last Updated: 09/26/2026